Crispina Calsada - 11 Jan 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Financial Officer
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
11 Jan 2023
Net transactions value
$0
Form type
4
Filing time
17 Jan 2023, 15:10:04 UTC
Previous filing
11 May 2022
Next filing
14 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +45,000 $0.000000 45,000 11 Jan 2023 Common Stock 45,000 $1.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.